Impact of quadrivalent influenza vaccine on public health and ă influenza-related costs in Australia

Aurelien Jamotte, Chui Fung Chong, Andrew Manton, Berengere Macabeo and Mondher Toumi
Additional contact information
Mondher Toumi: Pharmaco-Epidémiologie - Université Bordeaux Segalen - Bordeaux 2 - INSERM - Institut National de la Santé et de la Recherche Médicale

Post-Print from HAL

Abstract: Background: Annual trivalent influenza vaccines (TIV) containing three ă influenza strains (A/H1N1, A/H3N2, and one B) have been recommended for ă the prevention of influenza. However, worldwide co-circulation of two ă distinct B lineages (Victoria and Yamagata) and difficulties in ă predicting which lineage will predominate each season have led to the ă development of quadrivalent influenza vaccines (QIV), which include both ă B lineages. Our analysis evaluates the public health benefit and ă associated influenza-related costs avoided which would have been ă obtained by using QIV rather than TIV in Australia over the period ă 2002-2012. ă Methods: A static model stratified by age group was used, focusing on ă people at increased risk of influenza as defined by the Australian ă vaccination recommendations. B-lineage cross-protection was accounted ă for. We calculated the potential impact of QIV compared with TIV over ă the seasons 2002-2012 (2009 pandemic year excluded) using Australian ă data on influenza circulation, vaccine coverage, hospitalisation and ă mortality rates as well as unit costs, and international data on vaccine ă effectiveness, influenza attack rate, GP consultation rate and working ă days lost. Third-party payer and societal influenza-related costs were ă estimated in 2014 Australian dollars. Sensitivity analyses were ă conducted. ă Results: Using QIV instead of TIV over the period 2002-2012 would have ă prevented an estimated 68,271 additional influenza cases, 47,537 GP ă consultations, 3,522 hospitalisations and 683 deaths in the population ă at risk of influenza. These results translate into influenza-related ă societal costs avoided of \46.5 million. The estimated impact of QIV ă was higher for young children and the elderly. The overall impact of QIV ă depended mainly on vaccine effectiveness and the influenza attack rate ă attributable to the mismatched B lineage. ă Conclusion: The broader protection offered by QIV would have reduced the ă number of influenza infections and its related complications, leading to ă substantial influenza-related costs avoided.

Keywords: quality (search for similar items in EconPapers)
Date: 2016-07
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Published in BMC Public Health, 2016, 16, ⟨10.1186/s12889-016-3297-1⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-01482357

DOI: 10.1186/s12889-016-3297-1

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().